Among 15 participants with pancreatic cancer (PC) and BRCA1/2 mutations, 4 achieved partial responses, which was remarkable given the inclusion of heavily pretreated and platinum-refractory cases. This evidence concerns the gene BRCA1 and pachyonychia congenita.